Janux Q1 net loss $23.5M; initiates JANX007 Phase 1b expansion in mCRPC

Janux Therapeutics, Inc.

2025-Q1 EPS reported -$0.38

Initiated Phase 1b expansion with JANX007 in taxane-naïve mCRPC; updated median rPFS 7.5 months (n=16).
Cash and equivalents $1.01B at March 31, 2025, down from $1.03B at Dec 31, 2024.
R&D expenses $25.1M (Q1 2025) vs $14.1M (Q1 2024); net loss $23.5M vs $14.8M.
Additional JANX007 and JANX008 data expected in H2 2025; R&D Day planned mid-2025.
Selected two dose regimens (0.3/2/6mg and 0.3/2/9mg) for Phase 1b expansion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.